Oral Tranexamic Acid for Melasma: What to Review Before a Prescription

Oral tranexamic acid can improve melasma in selected patients, but a dermatologist needs to assess whether a prescription is appropriate. Its U.S. tablet indication is cyclic heavy menstrual bleeding; prescribing it for melasma is off-label. A serum containing tranexamic acid and a tablet require separate treatment discussions.[1][2]

What the 49% trial result measured

A 2018 randomized, double-blind trial enrolled 44 people with moderate-to-severe melasma; 39 completed it. Treatment was oral tranexamic acid or placebo with sunscreen for three months, then sunscreen alone for three months. Researchers measured the modified Melasma Area and Severity Index, or mMASI.[1]

At three months, the score had fallen by 49% in the tranexamic-acid group and 18% in the placebo group. Those percentages describe changes in a severity score. They do not mean that 49% of participants had clear skin. Three months after tablets stopped, the reductions from the original baseline were 26% and 19%, respectively.[1]

This single-center study predominantly enrolled Hispanic women and reported no serious adverse events. Its size cannot exclude uncommon harms. No GLP-1-treatment subgroup was reported.[1]

The prescription review needs your exact contraceptive

The U.S. label reviewed for this article contraindicates these tablets in females of reproductive potential using combined hormonal contraception. Its patient information specifies contraception containing estrogen and a progestin, including some pills, patches and vaginal rings. Bring the product name or a package photograph; “I use birth control” is insufficient detail. Do not stop contraception yourself to make a skin prescription possible.[2]

Other listed contraindications include an active clot, a history of thrombosis or thromboembolism, an intrinsic clotting risk, and allergy to tranexamic acid. Kidney impairment requires dosage adjustment under the label. The label also instructs patients with visual or eye symptoms to discontinue the tablets immediately and obtain prompt assessment, including ophthalmic evaluation.[2]

This is a reason to review the full medication list with the prescriber. A leftover prescription for heavy periods does not supply a melasma regimen. The two indications have different treatment contexts; this article does not provide a dose.

Confirm what is being treated

The American Academy of Dermatology advises that a dermatologist can distinguish melasma from another condition. Its treatment guidance discusses tranexamic acid when melasma is particularly difficult to treat and emphasizes discussing health history, including previous blood clots. Sun protection remains part of the treatment plan.[3]

If your appearance concerns arose during GLP-1 treatment, describe them separately: brown patches, acne marks, irritation and changes in facial fullness are different observations. Ask the clinician which diagnosis applies to each. The melasma trial does not establish that tranexamic acid treats facial-volume changes or prevents appearance changes during weight loss.

Four questions to take to the appointment

• “Which patches are melasma, and what supports that diagnosis?”
• “Given my medicines, contraceptive and health history, which options are suitable?”
• “What improvement would count as worthwhile, and how will we document it?”
• “When will we reassess treatment, and what is the plan if pigmentation returns after stopping?”

Bring dates and photographs of previous treatments, including products you stopped because of irritation. For the sunscreen discussion, see our melasma and tinted-sunscreen guide. These notes are appointment preparation, not a prescription or a replacement for assessment.

Printed book

How to Keep Your Face on GLP-1

$12.95 + free shipping

Order Now

✓ 30 day money back guarantee

This article provides general education, not a diagnosis or an individual treatment plan. Medication information refers to US sources. Discuss medication, nutrition and cosmetic treatment decisions with qualified clinicians.